杜瓦卢马布
医学
血液透析
不利影响
放射治疗
养生
免疫系统
癌症
内科学
肿瘤科
无容量
免疫疗法
免疫学
作者
Chihiro Yamada,Fumihiro Kashizaki,Mai Kaneko,Daiyu Kitaji,Naomi Kawano,Takeshi Kaneko
标识
DOI:10.1097/cad.0000000000001544
摘要
Durvalumab is the first immune check point inhibitor that was approved for use following concurrent platinum-based chemoradiation, in patients with unresectable stage III non-small cell lung cancer. The new treatment regimen of durvalumab administered after chemoradiation resulted in higher response rates and required careful immune-related adverse effects management. We experienced a rare case of severe acute kidney injury (AKI) requiring hemodialysis after only the first dose of durvalumab, in a patient who was diagnosed with immune-related AKI by renal biopsy. Although severe (Grade 3 or more) immune-related AKI occurred in 0.9% of patients treated with durvalumab, some drugs and radiation may increase immune-related AKI. Further research is needed to identify the clinical characteristics of patients who tend to develop severe AKI so as to prevent it, by reviewing such rare cases as ours.
科研通智能强力驱动
Strongly Powered by AbleSci AI